Skip to content
Study details
Enrolling now

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

Massachusetts General Hospital
NCT IDNCT05904132ClinicalTrials.gov data as of Apr 2026
Target enrollment

70

Study length

about 1.4 years

Ages

50–80

Locations

1 site in MA

What this study is about

Researchers are testing a device called tACS to see if it can help people with mild cognitive impairment, which may be related to Alzheimer's disease. The trial will involve using an EEG and questionnaires to monitor participants during trial visits. The goal is to assess how this closed-loop neuromodulation impacts natural gamma rhythms in patients with AD-MCI and their cognitive performance.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Use tACS device

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Body systems

Neurology